15 September 2016 | Features | By BioSpectrum Bureau
BioSpectrum Ranking Survey: Rank 5: Biological E
Total Revenue: Rs 1,018 crore
MD: Mahima Datla
Established in 1953, Biological E, claims to be the first private sector biological products company in India and the first pharmaceuticals company in South India.
Originally incorporated as Biological Products Private Limited, and launched by Dr Vijay Kumar Datla, Biological E (BE) is a significant leader in the world of vaccine market.
Based in Hyderabad, BE supplies several essential and lifesaving vaccines and pharmaceuticals to UN agencies viz. UNICEF, Pan American health organizations, other global markets and within India to Central and State government hospitals, public sector undertakings, the Indian Armed Forces and the domestic retail market.
BE crossed Rs 1,000 crore mark in revenue and clocked Rs 1,018 crore in revenue in the financial year FY15-16.
In addition to the impressive financial gains, the company has bagged a prestigious tender award of Rs 895 crore over the next two years for supplying 'ComBE Five', 5-in-1 Liquid Pentavalent Vaccine (LPV), to the Ministry of Health & Family Welfare, Government of India.
This vaccine would be inducted into the Government of India's Universal Immunization Program (UIP) and give a boost to Mission Indradhanush, an initiative to empower the UIP and extend full immunization coverage to at least 90 percent of all children of the country.
With scale up plans on the anvil and new business opportunities that present themselves, BE expects to register approximately 25 percent topline growth in the coming year.